Open AccessAn extended overall survival analysis of pemetrexed and carboplatin with or without pembrolizumab as first-line therapy for advanced non-squamous non-small cell lung cancer
Author(s) -
Muhammad Zubair Afzal,
Konstantin H. Dragnev,
Keisuke Shirai
Publication year - 2019
Publication title -
annals of translational medicine
Language(s) - English
Resource type - Journals
eISSN - 2305-5847
pISSN - 2305-5839
DOI - 10.21037/atm.2019.03.09
Subject(s) - pemetrexed , anaplastic lymphoma kinase , carboplatin , lung cancer , epidermal growth factor receptor , pembrolizumab , medicine , oncology , cancer research , targeted therapy , chemotherapy , cancer , cisplatin , immunotherapy , malignant pleural effusion
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom